Categories: Health

Financire de Tubize – 2025 half-year financial report

 | Source: Financière de Tubize SA

Half-year financial report 2025
Regulated information 2 August 2025

The board of directors of Financière de Tubize has established the 2025 half-year report. This report is available on the website www.financiere-tubize.be.

  • Profit for the first half of 2025: € 95.6 million (€ 92.9 million in 2024, + 2.8%),
  • Dividend received from UCB: € 98.1 million (€ 1.39 per share, an increase of 2.2% compared to the previous year),
  • 2024 Dividend paid to Financière de Tubize’s shareholders in 2025 of € 46.3 million (€ 1.04 per share, an increase of 7.22% compared to the previous year),
  • Acquisition, in 2025, of 24,487 UCB shares, for a total amount of € 4.37 million, at an average price of € 178.3. Our stake in UCB has increased from 36.27% on 31 December 2024 to 36,28% on 30 June 2025,
  • Decrease of outstanding bank borrowings from € 41.3 million at 31 December 2024 to € nil at 30 June 2025.
GlobeNews Wire

Recent Posts

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated

ZUG, Switzerland, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Ms. Kazem brings extensive and global expertise…

5 days ago

Novartis Vanrafia Phase III data support slowing of kidney function decline in patients with IgA nephropathy

Basel, February 13, 2026 – Novartis today announced final results from the Phase III ALIGN…

2 weeks ago

January Commercial Chapter 11 Filings Increase 76% Over 2025

NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- There were 956 commercial Chapter 11 filings…

2 weeks ago

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

Basel, February 6, 2026 – Novartis today broke ground on a new, state-of-the-art global Biomedical…

2 weeks ago

Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjgrens disease

Basel, January 16, 2026 – Novartis today announced that the US Food and Drug Administration (FDA)…

1 month ago

Personar Appoints Former Genius Sports COO Eric Stevens as Chief Operating Officer to Scale Award-Winning Sports Technology Platform

Tuesday 13 January, 2026 LONDON – Tuesday, January 13, 2026 – Personar, the AI sports…

1 month ago